To date, there are no specific therapeutic strategies for treatment of COVID-19.
Based on the hypothesis that complement and coagulation cascades are activated
by viral infection, and might trigger an acute respiratory distress syndrome
(ARDS), we report clinical outcomes of 17 consecutive cases of
SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of
ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an
anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of
three weeks, or with the best available therapy (N = 10). Patients treated with the
combination showed significant improvements in respiratory symptoms and
radiographic pulmonary lesions and decrease in circulating D-dimer levels
compared to the best available therapy group. Our results support the use of
combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related
ARDS by simultaneously turning off abnormal innate and adaptive immune
responses.

제 1편 코로나바이러스 정의
1. 코로나바이러스감염증-19(Covid-19) 정보 7
2. 코로나바이러스 분류 및 특성 9
3. 코로나바이러스 전자현미경 형태 11
4. 코로나바이러스 구조 (Covid-19 Organization) 13
5. 코로나19: 환경에 지속적인 영향을 미칠까? 19
6. 치료법(Therapeutical Method) 22

제 2편 연구논문
Combination of Ruxolitinib and Eculizumab for Treatment of Severe
SARS-CoV-2-Related Acute Respiratory Distress Syndrome:
A Controlled Study

1. INTRODUCTION 23
2. METHODS 24
3. Statistical Analysis 25
4. RESULTS AND DISCUSSION 26
5. DATA AVAILABILITY STATEMENT 27
6. ETHICS STATEMENT 27
7. ACKNOWLEDGMENTS 27
8. REFERENCES 27